Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

July 2, 2020, 2:09 p.m. EDT

Moderna's stock falls following report that the Phase 3 coronavirus vaccine trial has been delayed

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Moderna Inc. /zigman2/quotes/205619834/composite MRNA -3.97% declined 6.2% in trading on Thursday after people familiar with the matter told Stat News the start date for the company's Phase 3 clinical trial for its experimental COVID-19 vaccine has been delayed. The sources attributed the delay to protocol changes ⁠- a common issue with clinical studies ⁠- not a problem with the vaccine candidate. Following publication of the story, Moderna tweeted that the Phase 3 trial is still set to begin in July. "We have worked closely with [the National Institutes of Health/Operation Warp Speed] to align on the final protocol in order to begin the trial on time," it said . Moderna's stock has soared 197.7% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -2.14% is down 3.5%.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 152.68
-6.31 -3.97%
Volume: 5.72M
May 12, 2021 4:00p
P/E Ratio
121.75
Dividend Yield
N/A
Market Cap
$63.84 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,063.04
-89.06 -2.14%
Volume: 2.40B
May 12, 2021 5:03p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.